Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic and Therapeutic programs

Read more at globenewswire.com